Innate Pharma (IPHA) Profit After Tax (2019 - 2025)
Innate Pharma's (IPHA) quarterly Profit After Tax came in at -$57.2 million in Q4 2025, down 8.28% YoY from -$62.4 million in Q4 2024, and down 218.47% on a QoQ basis from $48.3 million in Q2 2025.
Innate Pharma (IPHA) Profit After Tax (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 7 years of Profit After Tax data on file, last reported at -$57.2 million in Q4 2025.
- Quarterly Profit After Tax fell 8.28% year-over-year to -$57.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$8.5 million (down 19.8% YoY) and the FY2025 annual result came in at -$57.2 million, down 8.28% from the prior year.
- Profit After Tax slipped to -$57.2 million in Q4 2025, from $48.3 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $57.1 million in Q2 2021 to a low of -$60.4 million in Q4 2021.
- A 5-year average of -$8.7 million and a median of -$8.1 million in 2023 frame the typical range for Profit After Tax.
- The widest YoY moves for Profit After Tax: up 8523.33% in 2024, down 549.05% in 2024.
- Tracing IPHA's Profit After Tax over 5 years: stood at -$60.4 million in 2021, then increased by 1.87% to -$59.3 million in 2022, then jumped by 86.26% to -$8.1 million in 2023, then tumbled by 549.05% to -$52.9 million in 2024, then decreased by 8.28% to -$57.2 million in 2025.
- The last three Profit After Tax figures came in at -$57.2 million (Q4 2025), $48.3 million (Q2 2025), and -$52.9 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | -57.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -57.24 Mn |
| Jun 30, 2025 | 48.32 Mn |
| Dec 31, 2024 | -52.86 Mn |
| Jun 30, 2024 | 53.34 Mn |
| Dec 31, 2023 | -8.14 Mn |
| Jun 30, 2023 | 618,509.05 |
| Dec 31, 2022 | -59.28 Mn |
| Dec 31, 2021 | -60.41 Mn |
| Jun 30, 2021 | 57.13 Mn |
| Dec 31, 2020 | -76.29 Mn |
| Jun 30, 2020 | -11.38 Mn |
| Dec 31, 2019 | -22.98 Mn |